It’s time for the JLC clan to choose who will join their team between Belle and Cassandra. Eventually, they choose Belle to destabilize the Guedj clan. Cassandra will join the other clan following the next trial. The strategy of the JLC clan works directly since a clash immediately breaks out between her and Maïssane. But it’s time for the clans to leave for the litmus test. All shots are allowed to win immunity! The Battle of Clans S01 Episode 03
Hydro-Quebec and its American partner won their case before the Supreme Court of Maine, which recognized that the referendum which said no to the interconnection project to Massachusetts was unconstitutional. But the road to this lucrative contract is still blocked by other legal pitfalls.
Posted at 2:45 p.m.
Updated at 5:59 p.m.
The court referred the case to a lower court, which will have to determine whether the permits and authorizations obtained by Avangrid, Hydro-Québec’s American partner, were obtained in accordance with laws and regulations and whether the company acted in good faith in the process. Additional delays that might jeopardize the Hydro-Québec contract are to be expected.
Construction work on the 233-kilometre line to connect Quebec to the State of Massachusetts, via Maine, was already well advanced when opponents from the State of Maine obtained the green light to allow the population to decide on the project by referendum.
At 59%, the opponents rejected the interconnection project and decided that this ban should apply retroactively to the start of the work during the popular consultation held on November 2, 2021.
It is this retroactivity that the Supreme Court has just ruled illegal. However, the referral of the case to the Superior Court of the State will cause additional delays which might be fatal for the Hydro-Québec contract.
It is too early to move forward on this issue, however, said Hydro-Quebec spokesperson Lynn Saint-Laurent. “What we can say is that the decision of the Supreme Court of Maine is favorable for the rest of things, but we are still in the middle of a legal process, she indicated. Take the time to analyze the decision. »
In addition to the referral to a trial court, Hydro-Quebec and its partner are awaiting another decision from the Supreme Court of Maine regarding a controversial lease on a 1.4 kilometer portion of the route on public lands.
“Hydro-Québec and its American partner NECEC Transmission LLC are currently studying the court decisions in order to determine the follow-up to be given, as well as the potential impacts on the construction schedule of the transmission line”, officially announced the two companies.
Massachusetts expects to receive its first deliveries of electricity from Quebec in 2024. There is “some leeway” on this side, Hydro-Québec said.
Opponents of the project, for their part, hope that the additional delays will discourage Massachusetts, which will turn to options other than that offered by Hydro-Québec. One of them, Tom Saviello, told local media that the fight once morest the interconnection project is a “marathon” with the last stages being the most difficult.
Hydro-Quebec and Avangrid have come up once morest the opposition of several environmentalists, but also a common front of electricity producers in the region, including Calpine, who fear losing ground to the benefit of renewable energies.
Works stopped
Avangrid, parent company of Central Maine Power, the state’s main electricity supplier, says it has already spent US$450 million on the construction of the transmission line, the total cost of which is estimated at US1.2 billion. Deforestation work was carried out and pylons were erected on portions of the route, before being stopped due to the referendum.
In Quebec, work estimated at $600 million on the Quebec portion of the transmission line to the 103-kilometre-long Maine border has been put on hold due to the blockage on the U.S. side.
The commissioning of the transmission line has been postponed several times. Hydro-Quebec has agreed to deliver 9.45 terawatt hours of electricity to Massachusetts for 20 years, a contract that should bring in several billion dollars in additional revenue. The average selling price of electricity is 8.8 cents per kilowatt hour, or double the industrial rate in Quebec.
The proposed transmission line through Maine is the alternative developed by Hydro-Quebec and its U.S. partner following their first route through New Hampshire, known as the Northern Pass, was rejected.
Al-Marsad newspaper: A court in the US state of Georgia is currently examining the case of an American woman named Movant Stacey Spagner who took advantage of the comprehensive health insurance for Saudi students who were visiting a center owned by her husband for physiotherapy and registered the provision of many health services that she did not provide to them, during the period between 2015 and mid-2021, according to A legal case study report by an American law specialist named Justin Anand.
According to the report, the fraud was discovered by the Tax Authority, which discovered suspicions of tax evasion and the inconsistency of what she pays in taxes with her income, and was referred for investigation, so she tried to procrastinate accusing her husband of mistreating her and forcing her to misuse insurance for Saudi students and to impose large expenses on their health insurance that exceed services The treatment that was already provided to them, as the Saudi students’ insurance was of the excellent category and covered 100% of the treatment services provided at the center, but the investigation authorities were not convinced of her innocence, and she was referred to the trial where she is still in progress, while her husband was sentenced to 51 months in prison, After that, he is subject to conditional release for 3 years. According to the newspaper “Mecca”.
Gemvax & KAEL, which developed ‘RiaVax’, a pancreatic cancer treatment, is gaining momentum in the development of Alzheimer’s treatment.
Gemvax & KAEL announced on the 30th that it will start a phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with moderate to severe Alzheimer’s disease, which was approved by the Ministry of Food and Drug Safety in January.
The clinical trial will be conducted on 936 patients with moderate to severe Alzheimer’s disease at 50 domestic hospitals, including Inha University Hospital.
He also explained that GemVax is ahead of phase 2 clinical trials overseas.
GemVax has confirmed the safety and effectiveness of GV1001 in patients with moderate to severe Alzheimer’s disease through a phase 2 clinical trial conducted at 12 domestic medical institutions from August 2017 to September 2019.
Statistical significance was confirmed in the superior improvement effect (7.1 points) of the primary endpoint, the Severe Disability Score (SIB), and the neuropsychiatric behavioral test (NPI), a secondary endpoint. In particular, clinically significant side effects and abnormalities in the GV1001 administration group The reaction has not been confirmed.
Gemvax published the results of the Phase 2 clinical trial in the online version of ‘Alzheimer’s Research & Therapy’, a world-renowned international academic journal that ranks in the top 10% of Alzheimer’s disease and an SCI-level international academic journal, in March last year.
A Gembex official said, “We are concentrating all our capabilities for the smooth progress of domestic and overseas clinical trials, and we will do our best until all clinical trials are completed.”
GV1001 was originally developed as an anticancer drug, but it is a new drug candidate under development as a treatment for Alzheimer’s disease through mechanisms such as anti-inflammatory, antioxidant and cytoprotective effects.
GemVax received conditional approval for ‘RiaVax’, a new drug for pancreatic cancer treatment, using GV1001, but the license was canceled in August 2020 because it failed to fulfill the conditions of approval.
Gemvax said that it is in the process of a phase 3 clinical trial for Liabex, and plans to apply for official approval to the Ministry of Food and Drug Safety as soon as the results are obtained.
By Kim Yong-joo, reporter [email protected]
ⓒ ‘Honest knowledge for health’ Comedy.com (https://kormedi.com) / Unauthorized reproduction-redistribution prohibited